Cervical Cancer Screening in China — HPV Genotyping + TCT

A bilingual, end-to-end cervical cancer screening pathway at Grade 3A hospitals in mainland China — designed for international women.

Cervical cancer is one of the most preventable cancers when caught early. This dedicated screening pairs the two gold-standard tests — HPV genotyping and ThinPrep liquid-based cytology (TCT) — with the logistical support that makes a screening abroad straightforward.

What's included (USD 159)

• HPV genotyping — identifies high-risk HPV strains (incl. 16/18) that drive the majority of cervical cancers
• Cervical TCT (ThinPrep liquid-based cytology) — detects abnormal cervical cells before they progress
• Appointment booking at a Grade 3A public hospital in mainland China (specific hospital confirmed in your service order)
• On-site exam guidance and navigation
• English report translation upon request

Who should screen

• Women aged 21–65 as routine preventive screening
• Women with a prior abnormal Pap/TCT or positive HPV result needing follow-up
• Women without recent access to screening in their home country

Co-testing (HPV + TCT together) offers the highest sensitivity for detecting cervical pre-cancer and is the approach recommended for most women aged 30 and over.